Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Fludarabine and Rituximab in patients with Chronic Lymphocytic Leukemia.

Statements

Source and description
Rituxan (rituximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rituximab in combination with fludarabine and cyclophosphamide for the treatment of previously untreated and previously treated CD20-positive Chronic Lymphocytic Leukemia (CLL).